AstraZeneca and Daiichi Sankyo have moved swiftly to file for FDA approval of a second indication for their TROP2-directed antibody-drug conjugate datopotamab deruxtecan (Dato-DXd), this time for ...
A biomarker could help identify patients with lung cancer who are most likely to benefit from treatment with AstraZeneca and Daiichi Sankyo's TROP2-directed drug datopotamab deruxtecan (Dato-DXd). The ...
Witnesses: Trump supporter flashed gun to crowd at Wilkes-Barre ‘No Kings’ protest City police arrested a man who flashed a gun to people protesting President Donald Trump’s administration at Saturday ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback